RSK2 Binding Models Delineate Key Features for Activity.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Chemical and Pharmaceutical Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 21593990PMCID PMC3094916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.

  2010cited by this paper
• Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.

  2009cited by this paper
• Structural Diversity of the Active N-Terminal Kinase Domain of p90 Ribosomal S6 Kinase 2

  2009cited by this paper
• A regulatory mechanism for RSK2 NH(2)-terminal kinase activity.

  2009cited by this paper
• Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

  2008cited by this paper
• Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2

  2008cited by this paper
• Targeting RSK: an overview of small molecule inhibitors.

  2008cited by this paper
• Et al

  2008cited by this paper
• The RSK family of kinases: emerging roles in cellular signalling

  2008cited by this paper
• Crystal structures of the N‐terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• A Ribosomal S-6 Kinase–Mediated Signal to C/EBP-β Is Critical for the Development of Liver Fibrosis

  2007cited by this paper
• Recruitment and Activation of RSK2 by HIV-1 Tat

  2007cited by this paper
• BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.

  2007cited by this paper
• Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.

  2006cited by this paper
• FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

  2006cited by this paper
• Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074.

  2006cited by this paper
• Identification of novel mutations in the RSK2 gene (RPS6KA3) in patients with Coffin–Lowry syndrome

  2006cited by this paper
• Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632.

  2006cited by this paper
• Mechanism of CDK5/p25 binding by CDK inhibitors.

  2005cited by this paper
• Synthesis of a potent and selective inhibitor of p90 Rsk.

  2005cited by this paper
• The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.

  2005cited by this paper
• Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

  2005cited by this paper
• Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.

  2005cited by this paper
• The c‐Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism

  2004cited by this paper
• Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125

  2004cited by this paper
• Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.

  2003cited by this paper
• ROCKs: multifunctional kinases in cell behaviour

  2003cited by this paper
• SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.

  2003cited by this paper
• Targeting JNK for therapeutic benefit: from junk to gold?

  2003cited by this paper
• Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity.

  2003cited by this paper
• Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor

  2002cited by this paper
• Rho-kinase as a Novel Therapeutic Target in Treatment of Cardiovascular Diseases

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

  2002cited by this paper
• Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension.

  2001cited by this paper
• A highly selective inhibitor of Rho-associated coiled-coil forming protein kinase, Y-27632, prolongs cardiac allograft survival of the BALB/c-to-C3H/He mouse model.

  2001cited by this paper
• SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

  2001cited by this paper
• A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

  2001cited by this paper
• Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain.

  2001cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Identification of serine 380 as the major site of autophosphorylation of Xenopus pp90rsk.

  1997cited by this paper
• The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase‐1β (Rsk‐2) and p70 S6 kinase

  1997cited by this paper
• Ro31‐8220 inhibits protein kinase C to block the phorbol ester‐stimulated release of choline‐ and ethanolamine‐metabolites from C6 glioma cells: p70 S6 kinase and MAPKAP kinase‐1β do not function downstream of PKC in activating PLD

  1997cited by this paper
• Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89

  1996cited by this paper
• AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR

  1996cited by this paper
• Comparison of the specificities of p70 S6 kinase and MAPKAP kinase‐1 identifies a relatively specific substrate for p70 S6 kinase: the N‐terminal kinase domain of MAPKAP kinase‐1 is essential for peptide phosphorylation

  1995cited by this paper
• A hot spot of binding energy in a hormone-receptor interface

  1995cited by this paper
• RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation

  1995cited by this paper
• Human rsk isoforms: cloning and characterization of tissue-specific expression.

  1994cited by this paper
• Shape changes and chemokinesis of Walker carcinosarcoma cells: effects of protein kinase inhibitors (HA-1004, polymyxin B, sangivamycin and tamoxifen) and an inhibitor of diacylglycerol kinase (R 59022).

  1993cited by this paper
• HINT: A new method of empirical hydrophobic field calculation for CoMFA

  1991cited by this paper
• Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase

  1989cited by this paper
• A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases.

  1988cited by this paper
• Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives.

  1987cited by this paper

• Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)

  2013cites this paper
• Molecular determinants of ligand binding at the human histamine H1 receptor: Site-directed mutagenesis results analyzed with ligand docking and molecular dynamics studies at H1 homology and crystal structure models.

  2012cites this paper